PAS
LRMR icon

Point72 Asia (Singapore)’s Larimar Therapeutics LRMR Stock Holding History

Point72 Asia (Singapore)’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$3.27K – 1072
2024
Q3 		$3.27K Buy
+500
New +$4.02K ﹤0.01% 891

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Point72 Asia (Singapore)'s LRMR Position: Q4 2024 in Review

Point72 Asia (Singapore) sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 500 shares — an estimated $3.27K sold.

Point72 Asia (Singapore) first reported a position in LRMR in Q3 2024 and held it in 1 quarter. The position peaked at $3.27K in Q3 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

  • Point72 Asia (Singapore) reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 500 Larimar Therapeutics shares in Q4 2024, an estimated $3.27K.
  • Point72 Asia (Singapore) first reported a position in Larimar Therapeutics in Q3 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Larimar Therapeutics position peaked at $3.27K in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q4 2024, filed 14 Feb 2025.